Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia

NCT00563290 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

7

Enrollment

NIH

Sponsor class

Conditions

Recurrent Skin Cancer
Squamous Cell Carcinoma of the Skin
Stage 0 Chronic Lymphocytic Leukemia
Stage I Chronic Lymphocytic Leukemia

Interventions

DRUG: dasatinib
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)